JS

Jean-Pierre Sommadossi

IP Idenix Pharmaceuticals: 37 patents #1 of 67Top 2%
UC Università Degli Studi Di Cagliari: 23 patents #1 of 61Top 2%
AP Atea Pharmaceuticals: 23 patents #1 of 4Top 25%
CN CNRS: 16 patents #33 of 11,908Top 1%
LI L'Universite Montpellier Ii: 8 patents #2 of 12Top 20%
EU Emory University: 8 patents #51 of 1,217Top 5%
TF The Uab Research Foundation: 7 patents #36 of 813Top 5%
TF The University Of Alabama Research Foundation: 2 patents #4 of 32Top 15%
UG University Of Georgia: 2 patents #194 of 915Top 25%
NA Novartis Ag: 2 patents #1,923 of 5,128Top 40%
BU Brown University: 1 patents #98 of 201Top 50%
UM Universite De Montpellier: 1 patents #213 of 699Top 35%
UB University Of Alabama At Birmingham: 1 patents #8 of 34Top 25%
UN Unknown: 1 patents #29,356 of 83,584Top 40%
C. C.N.R.S.: 1 patents #27 of 220Top 15%
📍 Boston, MA: #24 of 5,993 inventorsTop 1%
🗺 Massachusetts: #395 of 88,656 inventorsTop 1%
Overall (All Time): #21,932 of 4,157,543Top 1%
81
Patents All Time

Issued Patents All Time

Showing 1–25 of 81 patents

Patent #TitleCo-InventorsDate
12226429 Highly active compounds against COVID-19 Adel Moussa 2025-02-18
12134588 Crystalline epinephrine malonate salt Adel Moussa 2024-11-05
12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Adel Moussa 2024-09-10
12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus Adel Moussa 2024-06-11
11975016 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Adel Moussa 2024-05-07
11813278 Highly active compounds against COVID-19 Adel Moussa 2023-11-14
11738038 Highly active compounds against COVID-19 Adel Moussa 2023-08-29
11707480 Highly active compounds against COVID-19 Adel Moussa 2023-07-25
11690860 Treatment of HCV infected patients with cirrhosis Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou 2023-07-04
11505521 Crystalline epinephrine malonate salt Adel Moussa 2022-11-22
10995059 Crystalline epinephrine malonate salt Adel Moussa 2021-05-04
10946033 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Adel Moussa 2021-03-16
10906928 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Adel Moussa 2021-02-02
10894804 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Adel Moussa 2021-01-19
10874687 Highly active compounds against COVID-19 Adel Moussa 2020-12-29
10875885 β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment Adel Moussa 2020-12-29
10870673 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Adel Moussa 2020-12-22
10870672 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Adel Moussa 2020-12-22
10815266 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Adel Moussa 2020-10-27
10758557 Methods and compositions for treating hepatitis C virus Paolo La Colla 2020-09-01
10711029 Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection Adel Moussa 2020-07-14
10525072 2′-branched nucleosides and flaviviridae mutation Paolo La Colla, David Standring, Vadim Bichko, Lin Qu 2020-01-07
10519186 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Adel Moussa 2019-12-31
10363265 Methods and compositions for treating hepatitis C virus Paolo La Colla 2019-07-30
10239911 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Adel Moussa 2019-03-26